Identification

Name
Nitrendipine
Accession Number
DB01054  (APRD00421)
Type
Small Molecule
Groups
Approved, Investigational
Description

A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]

Structure
Thumb
Synonyms
  • 1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
  • BAY e 5009
  • Bayotensin
  • Baypress
  • Bylotensin
  • Deiten
  • Nidrel
  • Nitrendipino
  • Nitrendipinum
International/Other Brands
Bayotensin / Baypress / Deiten / Nidrel / Nitrepin / Nitrezic
Categories
UNII
9B627AW319
CAS number
39562-70-4
Weight
Average: 360.3612
Monoisotopic: 360.132136382
Chemical Formula
C18H20N2O6
InChI Key
PVHUJELLJLJGLN-UHFFFAOYSA-N
InChI
InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate hypertension

Structured Indications
Not Available
Pharmacodynamics

Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent calcium channel gamma-1 subunit
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

> 99%

Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nitrendipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nitrendipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nitrendipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitrendipine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Acebutolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nitrendipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
AliskirenNitrendipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nitrendipine.Approved, Withdrawn
AmbrisentanNitrendipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNitrendipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Nitrendipine.Approved
AmobarbitalThe metabolism of Nitrendipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nitrendipine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Nitrendipine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nitrendipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrendipine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitrendipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine.Approved
AtazanavirThe metabolism of Nitrendipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atenolol.Approved
AtomoxetineThe metabolism of Nitrendipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atosiban.Approved, Investigational
Atracurium besylateNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nitrendipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nitrendipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitrendipine.Experimental
BarbitalThe metabolism of Nitrendipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nitrendipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nitrendipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nitrendipine.Approved
BepridilNitrendipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Nitrendipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nitrendipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Nitrendipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nitrendipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Nitrendipine.Approved
BoceprevirThe metabolism of Nitrendipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Nitrendipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.Approved
BQ-123Nitrendipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Nitrendipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.Approved
BretyliumNitrendipine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nitrendipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nitrendipine.Experimental
BucindololBucindolol may increase the hypotensive activities of Nitrendipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Nitrendipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine.Approved, Investigational
BupranololNitrendipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nitrendipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nitrendipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nitrendipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Nitrendipine.Experimental
CafedrineNitrendipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Canagliflozin.Approved
CandesartanNitrendipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Nitrendipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nitrendipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Nitrendipine.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Nitrendipine.Experimental
CaptoprilNitrendipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Nitrendipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine.Approved
CarbomycinThe metabolism of Nitrendipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nitrendipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Nitrendipine.Approved
CarvedilolNitrendipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine.Approved
CeliprololNitrendipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nitrendipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nitrendipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrendipine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nitrendipine.Approved
CicletanineNitrendipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nitrendipine.Approved, Investigational
CilazaprilNitrendipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine.Approved, Investigational
CimetidineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nitrendipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.Approved, Nutraceutical
CloranololNitrendipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nitrendipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitrendipine.Approved
CobicistatThe metabolism of Nitrendipine can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nitrendipine.Approved
ConivaptanThe serum concentration of Nitrendipine can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nitrendipine.Investigational
CrizotinibThe metabolism of Nitrendipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nitrendipine.Approved
CyclopenthiazideNitrendipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nitrendipine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine.Approved
DabrafenibThe serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nitrendipine.Investigational
DarunavirThe metabolism of Nitrendipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
DeferasiroxThe serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilNitrendipine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Nitrendipine can be decreased when combined with Delavirdine.Approved
DeserpidineNitrendipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nitrendipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Nitrendipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Diclofenamide.Approved
diethylnorspermineNitrendipine may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Nitrendipine.Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nitrendipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nitrendipine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nitrendipine.Experimental
DihydroergotamineThe metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Nitrendipine can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nitrendipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Nitrendipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine.Approved, Investigational
DoxycyclineThe metabolism of Nitrendipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Nitrendipine can be decreased when combined with Dronedarone.Approved
DuloxetineNitrendipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nitrendipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.Approved
EfavirenzThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nitrendipine.Approved
EfonidipineNitrendipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
EnalaprilatNitrendipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nitrendipine.Experimental
EnzalutamideThe serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.Approved
EpanololNitrendipine may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Eplerenone.Approved
EpoprostenolNitrendipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Nitrendipine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nitrendipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nitrendipine.Approved
ErythromycinThe metabolism of Nitrendipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.Approved
FelodipineFelodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Nitrendipine.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Nitrendipine.Experimental
Ferulic acidNitrendipine may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine.Approved, Investigational
FluconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nitrendipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Nitrendipine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Nitrendipine.Approved
FluvoxamineThe metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nitrendipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Nitrendipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nitrendipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nitrendipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nitrendipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Nitrendipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nitrendipine.Approved
GuanazodineNitrendipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineNitrendipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
GuanoclorNitrendipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNitrendipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNitrendipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Nitrendipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nitrendipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nitrendipine.Experimental
HexamethoniumNitrendipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nitrendipine.Approved, Investigational
HexobarbitalThe metabolism of Nitrendipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nitrendipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Nitrendipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ImatinibThe metabolism of Nitrendipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitrendipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Nitrendipine.Approved
IndenololNitrendipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nitrendipine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Nitrendipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nitrendipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nitrendipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nitrendipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitrendipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nitrendipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Nitrendipine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Nitrendipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor.Approved
JosamycinThe metabolism of Nitrendipine can be decreased when combined with Josamycin.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Nitrendipine.Investigational
KetoconazoleThe metabolism of Nitrendipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Nitrendipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Nitrendipine.Approved
LacidipineNitrendipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine.Approved, Investigational
LevodopaNitrendipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine.Approved, Investigational
LinsidomineNitrendipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Nitrendipine.Approved, Investigational
LofexidineNitrendipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Losartan.Approved
LovastatinThe metabolism of Nitrendipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nitrendipine can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nitrendipine.Illicit, Investigational, Withdrawn
MacitentanNitrendipine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNitrendipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nitrendipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nitrendipine.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Nitrendipine.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Nitrendipine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Nitrendipine can be increased when combined with Methohexital.Approved
MethoserpidineNitrendipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Nitrendipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitrendipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitrendipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Nitrendipine can be increased when combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Nitrendipine.Approved
MetipranololNitrendipine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Nitrendipine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Metoprolol.Approved, Investigational
MetyrosineNitrendipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nitrendipine.Experimental
MibefradilNitrendipine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nitrendipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Nitrendipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nitrendipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Nitrendipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nitrendipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nitrendipine.Investigational
MitotaneThe serum concentration of Nitrendipine can be decreased when it is combined with Mitotane.Approved
MivacuriumNitrendipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nitrendipine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Nitrendipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nitrendipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrendipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MuzolimineNitrendipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nitrendipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nadolol.Approved
NafcillinThe metabolism of Nitrendipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nitrendipine.Approved
NaftopidilNitrendipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nitrendipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nitrendipine.Approved
NebivololNitrendipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Nitrendipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nitrendipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nitrendipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nitrendipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nitrendipine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Nitrendipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Nitrendipine.Experimental
NiguldipineNitrendipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Nitrendipine.Investigational
NilotinibThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNitrendipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Nitrendipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nitrendipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitrendipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nitrendipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nitrendipine.Approved, Vet Approved
ObinutuzumabNitrendipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nitrendipine.Withdrawn
OlaparibThe metabolism of Nitrendipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nitrendipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Nitrendipine.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Nitrendipine.Experimental
OsimertinibThe serum concentration of Nitrendipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nitrendipine.Approved
OxprenololNitrendipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nitrendipine.Investigational
PalbociclibThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Nitrendipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.Approved
PenbutololNitrendipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine.Approved
PentobarbitalThe metabolism of Nitrendipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumNitrendipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nitrendipine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Nitrendipine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Nitrendipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nitrendipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PhenobarbitalThe metabolism of Nitrendipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nitrendipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nitrendipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Nitrendipine.Withdrawn
PindololPindolol may increase the hypotensive activities of Nitrendipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Nitrendipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nitrendipine.Withdrawn
Platelet Activating FactorNitrendipine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideNitrendipine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Nitrendipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Prazosin.Approved
PrimidoneThe metabolism of Nitrendipine can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Nitrendipine.Approved
PropofolThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nitrendipine.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Nitrendipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nitrendipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nitrendipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Nitrendipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nitrendipine.Approved, Investigational
RapacuroniumNitrendipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nitrendipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nitrendipine.Approved
RescinnamineNitrendipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Nitrendipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nitrendipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nitrendipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nitrendipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nitrendipine.Investigational
RiociguatNitrendipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneNitrendipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabNitrendipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nitrendipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nitrendipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nitrendipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nitrendipine.Approved, Vet Approved
SaprisartanNitrendipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Nitrendipine can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Nitrendipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nitrendipine.Approved, Investigational, Vet Approved
SelexipagNitrendipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nitrendipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.Approved
SiltuximabThe serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nitrendipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nitrendipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nitrendipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine.Approved, Investigational
SitaxentanNitrendipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Nitrendipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol.Approved
SpiraprilNitrendipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Nitrendipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nitrendipine.Approved
SulfisoxazoleThe metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
TalinololNitrendipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nitrendipine.Approved
TelaprevirThe metabolism of Nitrendipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Nitrendipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TemocaprilNitrendipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Nitrendipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nitrendipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nitrendipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Nitrendipine.Experimental
TerlipressinNitrendipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineNitrendipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineNitrendipine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Nitrendipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nitrendipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine.Approved, Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nitrendipine.Approved
TiboloneNitrendipine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Nitrendipine can be decreased when combined with Ticlopidine.Approved
TicrynafenNitrendipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nitrendipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Nitrendipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nitrendipine.Approved, Vet Approved
TolonidineNitrendipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nitrendipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nitrendipine.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Nitrendipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Nitrendipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitrendipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nitrendipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Nitrendipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nitrendipine.Approved, Investigational
TylosinThe metabolism of Nitrendipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Nitrendipine.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
UnoprostoneNitrendipine may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Nitrendipine.Investigational
Ursodeoxycholic acidUrsodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nitrendipine.Approved
VenlafaxineThe metabolism of Nitrendipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Nitrendipine can be decreased when combined with Verapamil.Approved
VincamineNitrendipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nitrendipine.Approved, Investigational
VinpocetineNitrendipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Nitrendipine can be decreased when combined with Voriconazole.Approved, Investigational
XipamideNitrendipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineNitrendipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nitrendipine.Approved, Vet Approved
ZiprasidoneThe metabolism of Nitrendipine can be decreased when combined with Ziprasidone.Approved
ZofenoprilNitrendipine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.

US4724141
General References
Not Available
External Links
Human Metabolome Database
HMDB15187
KEGG Drug
D00629
KEGG Compound
C07713
PubChem Compound
4507
PubChem Substance
46508817
ChemSpider
4351
BindingDB
50012016
ChEBI
7582
ChEMBL
CHEMBL475534
Therapeutic Targets Database
DAP001263
PharmGKB
PA146096020
IUPHAR
2334
Guide to Pharmacology
GtP Drug Page
Wikipedia
Nitrendipine
ATC Codes
C09BB06 — Enalapril and nitrendipineC08CA08 — Nitrendipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)1
4WithdrawnTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)156-160 °CNot Available
water solubilityInsolubleNot Available
logP2.88MASUMATO,K ET AL. (1995)
Caco2 permeability-4.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0142 mg/mLALOGPS
logP3.21ALOGPS
logP2.17ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity96.91 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9536
Blood Brain Barrier-0.9549
Caco-2 permeable+0.7853
P-glycoprotein substrateSubstrate0.5265
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8313
Renal organic cation transporterNon-inhibitor0.8984
CYP450 2C9 substrateNon-substrate0.8212
CYP450 2D6 substrateNon-substrate0.8931
CYP450 3A4 substrateSubstrate0.7266
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.8037
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9247
Ames testNon AMES toxic0.7334
CarcinogenicityNon-carcinogens0.5186
BiodegradationNot ready biodegradable0.9581
Rat acute toxicity2.3810 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8131
hERG inhibition (predictor II)Non-inhibitor0.9094
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ab9-2539000000-3d9a9111a145f234fc24
MS/MS Spectrum - , positiveLC-MS/MSsplash10-016r-0159000000-7b0ccf9fb639868092f0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016r-0159000000-4e10a6643ba97ab23a0f

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines
show 6 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, ethyl ester, diester, dihydropyridine (CHEBI:7582)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  2. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:46